Genentech Inc Company Profile
What is the competitive landscape for GENENTECH INC
GENENTECH INC has eight approved drugs.
There are forty-five US patents protecting GENENTECH INC drugs.
Summary for Genentech Inc
| US Patents: | 45 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 8 |
Drugs and US Patents for Genentech Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | EVRYSDI | risdiplam | FOR SOLUTION;ORAL | 213535-001 | Aug 7, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Genentech Inc | ROZLYTREK | entrectinib | PELLETS;ORAL | 218550-001 | Oct 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | 9,255,087 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Genentech Inc | XOFLUZA | baloxavir marboxil | FOR SUSPENSION;ORAL | 214410-003 | May 30, 2025 | RX | Yes | Yes | 8,987,441 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Genentech Inc | EVRYSDI | risdiplam | FOR SOLUTION;ORAL | 213535-001 | Aug 7, 2020 | RX | Yes | Yes | 11,827,646 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genentech Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | 11,597,699 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Genentech Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2990222 | ⤷ Start Trial |
| South Korea | 20080050601 | ⤷ Start Trial |
| Japan | 6335169 | ⤷ Start Trial |
| Ukraine | 96742 | ⤷ Start Trial |
| European Patent Office | 3290414 | ⤷ Start Trial |
| Serbia | 67509 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genentech Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1934174 | SPC/GB16/023 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: COBIMETINIB, INCLUDING A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR COBIMETINIB HEMIFUMARATE; REGISTERED: UK EU/1/15/1048/001(NI) 20151124; UK PLGB 00031/0849 20151124 |
| 2620436 | 202140003 | Slovenia | ⤷ Start Trial | PRODUCT NAME: BALOXAVIR MARBOXIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/20/1500; DATE OF NATIONAL AUTHORISATION: 20210107; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2620436 | 301093 | Netherlands | ⤷ Start Trial | PRODUCT NAME: BALOXAVIR MARBOXIL, ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN ERVAN; REGISTRATION NO/DATE: EU/1/20/1500 20210108 |
| 2176231 | 122020000081 | Germany | ⤷ Start Trial | PRODUCT NAME: ENTRECTINIB ODER ISOMERE, TAUTOMERE ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1460 20200731 |
| 3317284 | 202540033 | Slovenia | ⤷ Start Trial | PRODUCT NAME: INAVOLISIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/25/1942; DATE OF NATIONAL AUTHORISATION: 20250718; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 3107541 | 132021000000107 | Italy | ⤷ Start Trial | PRODUCT NAME: ENTRECTINIB IN TUTTE LE SUE FORME PROTETTE DAL BREVETTO DI BASE: ENTRECTINIB O SUOI ISOMERI, TAUTOMERI O SALI FARMACEUTICAMENTE ACCETTABILI(ROZLYTREK ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1460, 20200803 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
